Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 50Leukemia 27Myelodysplastic Syndromes 13Leukemia, Erythroblastic, Acute 11Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 10Leukemia, Megakaryoblastic, Acute 10Congenital Abnormalities 9Anemia, Refractory, with Excess of Blasts 5Leukemia, Eosinophilic, Acute 4Leukemia, Basophilic, Acute 4Recurrence 3Leukemia, Promyelocytic, Acute 3Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Disease 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Recurrence × Gemtuzumab × Clear all
NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Big Ten Cancer Research Consortium

Phase 1 Completed
18 enrolled 15 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04173585 2023-03-27

TEAM

University Hospital Heidelberg

Phase 2 Completed
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00233909 2008-04-01

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Kanisa Pharmaceuticals

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡